Altered expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in high-risk soft tissue sarcomas

Histology and Histopathology

Volumn 22, Issue 7-9, 2007, Pages 1017-1024

  Benassi, Maria Serena ^a   Ponticelli, F ^a   Azzoni, E ^a   Gamberi, G ^a   Pazzaglia, L ^a   Chiechi, A ^a   Conti, A ^a   Spessotto, P ^b   Scapolan, M ^b   Pignotti, E ^a   Bacchini, P ^a   Picci, P ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Immunohistochemistry; mRNA expression; Soft tissue sarcomas; uPA system

Indexed keywords

MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE; UROKINASE RECEPTOR; CELL SURFACE RECEPTOR; PLASMINOGEN ACTIVATOR, UROKINASE RECEPTORS; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; METASTASIS POTENTIAL; PHENOTYPE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REFERENCE VALUE; SOFT TISSUE SARCOMA; UPREGULATION; CASE CONTROL STUDY; CLASSIFICATION; COMPARATIVE STUDY; CULTURE TECHNIQUE; DISEASE FREE SURVIVAL; FOLLOW UP; GENE EXPRESSION; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; RISK FACTOR; SARCOMA; TIME; TUMOR CELL LINE;

ADULT; AGED; CASE-CONTROL STUDIES; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMERASE CHAIN REACTION; RECEPTORS, CELL SURFACE; RISK FACTORS; RNA, MESSENGER; SARCOMA; TIME FACTORS; URINARY PLASMINOGEN ACTIVATOR;

EID: 34447128091     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Andreasen P.A., Egelund R. and Petersen H.H. (2000). The plasminogen activation system in tumor growth, invasion and metastasis. Cell. Mol. Life Sci. 57, 25-40.
2. Benassi M.S, Magagnoli G., Ponticelli F., Pazzaglia L., Zanella L., Gamberi G., Ragazzini P., Ferrari C., Mercuri M. and Picci P. (2003). Tissue and serum loss of metalloproteinase inhibitors in high grade soft tissue sarcoma. Histol. Histopathol. 18, 1035-1040.
3. Borden E.C., Baker L.H., Bell R.S., Bramwell V., Demetri G.D., Eisenberg B.L., Fletcher C.D., Fletcher J.A., Ladany M., Meltzer P., O'Sullivan B., Parkinson D.R., Pisters P.W., Saxman S. (2003). Soft tissue sarcomas of adults: state of translational science. Clin. Cancer Res. 9, 1941-1956.
4. Campanacci M. (1999). Soft tissue tumors. In: Bone and soft tissue tumors. 2nd edn. Springer-Verlag. Wien, New York. pp 909-1199.
5. Choong P.F., Ferno M., Akerman M., Willen H., Langstrom E., Gustafson P., Alvegard T. and Rydholm A. (1996). Urokinase-plasminogen-activator levels and prognosis in 69 soft-tissue sarcomas. Int. J. Cancer 69, 268-272.
6. Dirix L.Y. and van Oosterom A.T. (2002). Gene-expression profiling to classify soft tissue sarcomas. Lancet 359, 1263-1264.
7. Duffy M.J. (2002). Urokinase plasminogen activator and its imhibitor PAI-I, as prognostic markers in breast cancer: from pilot to level I evidence studies. Clin. Chem. 48, 1194-1197.
8. Duffy M.J. (2004). The urokinase plasminogen activator system: role in malignancy. Curr. Pharm. Des. 10, 39-49.
9. Duffy M.J., Maguire T.M., McDermott E.W. and O'Higgins N. (1999). Urokinase plasminogene activator: a prognostic marker in multiple types of cancer. J. Surg. Oncol. 71, 130-135.
10. Durand M.K., Bodker J.S., Christensen A., Dupont D.M., Hansen M., Jensen J.K., Kjelgaard S., Mathiasen L., Pedersen K.E., Skeldal S., Wind T. and Andreasen P.A. (2004). Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis. Thromb. Haemost. 91, 438-449.
11. Fletcher C.D.M., Unni K.K. and Mertens F. (2002). So-called fibrohistocytic tumors and Smooth muscle tumors. In: WHO classification of Tumors: pathology and genetics of tumors of soft tissue and bone. Fletcher C.D.M., Unni K.K. and Mertens F. (eds). IARC Press. Lyon. pp 109-131.
12. Frustaci S., Gherlinzoni F., De Paoli A., Bonetti M., Azzarelli A., Comandone A., Olmi P., Buonadonna A., Pignatti G., Apice G., Zmerly A., Serraino, D. and Picci P. (2001). Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J. Clin. Oncol. 19, 1238-1247.
13. Gamberi G., Serra M., Ragazzini P., Magagnoli G., Pazzaglia L., Ponticelli F., Ferrari C., Zanasi M., Bertoni F., Picci P. and Benassi M.S. (2003). Identification of markers of possible prognostic value in 57 giant cell tumors of bone. Oncol. Rep 10, 351-356.
14. Gamberi G., Benassi M.S., Ragazzini P., Pazzaglia L., Ponticelli F., Ferrari C., Balladelli A., Mercuri M., Gigh M., Bertoni F. and Picci P. (2004). Proteases and interleukin-6 gene analysis in 92 giant cell tumors of bone. Ann. Oncol. 15, 498-503.
15. Gils A. and Declerck P.J. (2004). Structure, function and pathophysiological relevance of plasminogen activator inhibitor-1. Thromb. Haemost. 91, 425-437.
16. Helman L.J. and Meltzer P. (2003). Mechanisms of sarcoma development. Nature Rev. 3, 685-694.
17. Lehmann U., Glockner S., Kleeberger W., Feist H., von Wasielewski R. and Kreipe H. (2000). Detection of gene amplification in archivial breast cancer specimens by laser-assisted microdissection and quantitative Real-Time polymerase chain reaction. Am. J. Pathol. 156, 1855-1864.
18. Memarzadeh S., Kozak K.R., Chang L., Natarajan S., Shintaku P., Reddy S.T. and Farias-Eisner R. (2002). Urokinase plasminogen activator receptor: prognostic biomarker for endometrial cancer. Proc. Natl. Acad. Sci. USA 99, 10647-1052.
19. Mignatti P. and Rifkin D.B. (1993). Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 73, 161-195.
20. Nielsen T.O., West R.B., Linn S.C., Alter O., Knowling M.A., O'connell J.X., Zhu S., Fero M., Sherlock G., Pollack J.R., Brown P.O., Botstein D. and van de Rijn M. (2002). Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 359, 1301-1307.
21. Orlando C., Pinzani P. and Pazzagli M. (1998). Developments in quantitative PCR. Clin. Chem. Lab. Med. 36, 255-269.
22. Ploug M. (2003). Structure-function relationship in the interaction between the urokinase-type plasminogen activator and its receptor. Curr. Pharm. Des. 9, 1499-1528.
23. Romer M.U., Kirkebjerg Due A., Knud Larsen J., Hofland K.F., Christensen I.J., Buhl-Jensen P., Almholt K., Lerberg Nielsen O., Brunner N. and Lademann U. (2005). Indication of a role of plasminogen activator inhibitor type I in protecting murine fibrosarcoma cells against apoptosis. Thromb. Haemost. 94, 859-866.
24. Schmitt M., Harbeck N., Thomssen C., Wilhelm O., Magdolen V., Reuning U., Ulm K., Hofler H., Janicke F. and Graeff H. (1997). Clinical impact of the plasminogen activator system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb. Haemost. 78, 285-296.
25. Seetoo D.Q., Crowe P.J., Russell P.J. and Yang J.L. (2003). Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. J. Surg. Oncol. 82, 184-193.
26. Stefansson S., McMahon G.A., Petitclerc E. and Lawrence D.A. (2003). Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr. Pharm. Des. 9, 1545-1564.
27. Stetler-Stevenson W.G., Hewitt R. and Corcoram M. (1996), Matrix Metalloproteinases and tumor invasion: from correlation and casuality to the clinic. Sam. Cancer. Biol. 7, 147-154.
28. Winer J., Jung C.K., Shackel I. and Williams P.M. (1999). Development and validation of Real-Time quantitative reverse trascriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal. Blochem. 270, 41-49.